Genicular Artery Embolization (GAE)
Non-surgical relief for chronic knee osteoarthritis pain.
Learn more →Expanding access to embolization-based therapies for chronic knee pain, liver cancer, BPH, and complex vascular disease. Minimally invasive, image-guided alternatives to major surgery, performed through a pinhole.
My job is to give patients real options. As Division Chief of Interventional Radiology at Rutgers New Jersey Medical School, I’ve spent the past decade turning that idea into new clinical programs, active research trials, and referral networks that didn’t exist in New Jersey before my team built them.
At Rutgers, I’ve grown New Jersey’s largest Y90 radioembolization practice, one that now receives referrals from institutions across the state. I was among the first interventional radiologists in New Jersey to adopt radial (wrist) access for non-coronary interventions, and I co-direct the TRAIN CME course teaching the technique to peers across the region. I also launched one of the region’s first genicular artery embolization programs, featured in television and media coverage for its impact on patients with chronic knee osteoarthritis.
What I care about most is working across specialty lines. The best outcomes I’ve seen come from sitting down with orthopedic surgeons, hepatologists, gastroenterologists, and pain management physicians to design pathways that put the right procedure in front of the right patient. If you’re a physician exploring how embolization could complement your practice, or a patient looking for a non-surgical option, I’d welcome that conversation.
Every procedure below is performed through a pinhole incision, guided by real-time imaging. All are outpatient. Same-day discharge. Local anesthesia only, no sedation. Click any card to learn more.
Non-surgical relief for chronic knee osteoarthritis pain.
Learn more →A minimally invasive alternative to TURP for BPH.
Learn more →Uterus-sparing treatment for symptomatic fibroids.
Learn more →Non-surgical, image-guided treatment for symptomatic hemorrhoids.
Learn more →Image-guided cancer therapies — Y90, TACE, ablation, and tumor embolization.
Learn more →Site Principal Investigator on NIH-funded and industry-sponsored trials in pulmonary embolism, portal hypertension, and embolic therapy. Selected publications from 53+ peer-reviewed articles.
Education has been a core part of my career. I founded the New Jersey Interventional Radiology Symposium for medical students in 2018, and direct CME courses that bring practicing physicians from across the region together to learn new techniques. Nationally, I have served as Chair of the Society of Interventional Radiology (SIR) Early Career Section, course faculty at SIR and RSNA annual meetings, and an invited proctor for hospitals building Y90 programs.
A selection of recent media coverage and institutional profiles. Click any card to open in a new tab.
GAE is a minimally invasive, outpatient procedure for patients with moderate-to-severe knee osteoarthritis pain that no longer responds well to medications, physical therapy, or injections — and who are not ready for, or not candidates for, total knee replacement.
In an osteoarthritic knee, the lining of the joint becomes inflamed and grows an abnormal network of small blood vessels. These vessels release inflammatory signals and pain mediators that drive much of the chronic pain people feel — even when imaging suggests only mild arthritis. GAE uses tiny embolic particles, delivered through a catheter the width of a strand of spaghetti, to selectively block these abnormal vessels. Pain falls because the inflammatory engine is turned down.
Patients go home the same day, usually within a few hours of the procedure. Most return to desk work the next day and to normal activity within 2–3 days. Pain improvement is typically gradual over 4–8 weeks as inflammation resolves, with continued improvement out to 6 months.
GAE is supported by a growing body of published evidence including multi-center randomized trials. It does not damage cartilage, does not preclude a future knee replacement, and is performed without general anesthesia — making it an appealing bridge or alternative for the right patient.
PAE is a minimally invasive, outpatient treatment for men whose lower urinary tract symptoms from benign prostatic hyperplasia (BPH) — frequent urination, weak stream, urgency, nighttime trips to the bathroom, incomplete emptying — are not adequately controlled with medication and who want to avoid traditional surgery.
An enlarged prostate compresses the urethra and obstructs urine flow. PAE delivers tiny embolic particles through the small arteries that feed the prostate, reducing its blood supply. Over the following weeks the prostate gradually shrinks and softens, which relieves the obstruction and improves urinary symptoms without cutting, burning, or removing prostate tissue.
Most men go home the same day without a urinary catheter. Mild pelvic discomfort, a low-grade fever, or some urinary urgency for a few days is common and self-limited. Return to desk work in 2–3 days. Urinary symptoms typically begin improving within 2–4 weeks, with maximal benefit at 3–6 months as the gland shrinks.
Unlike many surgical options for BPH, PAE carries minimal risk of urinary incontinence and rarely affects ejaculation or erections. There is no resected tissue, no urethral instrumentation, and no general anesthesia. For the right patient, it offers durable symptom relief with a fraction of the recovery.
UFE is a minimally invasive, uterus-sparing treatment for women with symptomatic uterine fibroids — including heavy or prolonged menstrual bleeding, pelvic pressure or pain, urinary frequency, and bulk-related discomfort. It is an established alternative to hysterectomy and myomectomy.
Fibroids depend on a rich blood supply from the uterine arteries. UFE delivers small embolic particles through a catheter into both uterine arteries, blocking blood flow to the fibroids while leaving the normal uterus and ovaries intact. Deprived of their supply, fibroids shrink, soften, and become symptom-free over the following months. Bleeding-related symptoms typically improve much sooner.
Most patients go home the same day with a structured pain plan for the cramping that can occur in the first 24 to 48 hours. Return to normal activity within 7–10 days. Heavy bleeding improves within the first 1–2 cycles, with bulk-related symptoms and fibroid size reduction continuing over 3–6 months.
UFE has been studied for decades, with strong long-term outcomes data. It avoids general anesthesia, preserves the uterus, and requires no surgical incision. For women who want symptom relief without the recovery and impact of hysterectomy, it is a well-established option supported by major gynecologic and radiology societies.
HAE — sometimes called the Emborrhoid technique — is a minimally invasive treatment for internal hemorrhoids that bleed, prolapse, or fail to respond to creams, banding, or dietary changes. There are no incisions in the anal region, no cutting of sensitive tissue, and no painful recovery.
Internal hemorrhoids form when the small arteries feeding the hemorrhoidal cushions deliver more blood than the veins can drain, causing the cushions to enlarge, bleed, and eventually prolapse. HAE uses a catheter advanced from the wrist or groin to reach the small rectal arteries that supply these cushions. Tiny coils or particles reduce that arterial inflow, allowing the hemorrhoids to shrink and stop bleeding — without ever touching the anus itself.
Patients go home the same day. Because the procedure does not involve any cutting or instrumentation of the anal canal, the painful recovery associated with traditional surgery does not occur. Most patients return to normal activity the next day. Bleeding typically improves within days to weeks; prolapse symptoms improve more gradually.
Compared to surgical hemorrhoidectomy, HAE carries minimal post-procedure pain and a much faster return to work. For patients who simply cannot tolerate surgical recovery — or who are managing other conditions that complicate surgery — it offers a meaningful, evidence-supported alternative.
Interventional oncology brings cancer therapy directly to the tumor through the blood vessels or with a needle, sparing healthy tissue and avoiding open surgery. Our program at Rutgers is the largest Y90 radioembolization practice in New Jersey, with referrals from across the state for complex primary and metastatic liver disease.
Tumors require a blood supply to grow. That same blood supply is a delivery route for targeted therapy. Using catheters threaded under imaging guidance, interventional oncologists can deliver radiation (Y90 radioembolization), chemotherapy (TACE), or embolic particles directly into the artery that feeds a tumor. When a vascular approach is not ideal, we treat tumors percutaneously with thermal ablation — microwave or cryoablation — guided by CT or ultrasound. All of this is decided multidisciplinarily, alongside surgical and medical oncology.
Recovery depends on the specific therapy. Most patients go home the same day and return to normal activity within a week. Fatigue, mild nausea, or right upper-quadrant discomfort after liver-directed therapy are common and self-limited. We coordinate post-procedure imaging at 1 and 3 months to assess tumor response.
Interventional oncology lets us treat patients who are not candidates for surgery, treat tumors precisely without affecting the rest of the body, and combine with systemic therapy and surgery as part of a larger plan. Our Rutgers program also gives patients access to clinical trials including the EMERALD Y90 study combining radioembolization with immunotherapy for unresectable HCC.